258 related articles for article (PubMed ID: 17484074)
21. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents.
Quindós G; Carrillo-Muñoz AJ; Arévalo MP; Salgado J; Alonso-Vargas R; Rodrigo JM; Ruesga MT; Valverde A; Pemán J; Cantón E; Martín-Mazuelos E; Pontón J
Chemotherapy; 2000; 46(6):395-401. PubMed ID: 11053905
[TBL] [Abstract][Full Text] [Related]
22. Taxonomic and diagnostic markers for identification of Coccidioides immitis and Coccidioides posadasii.
Tintelnot K; De Hoog GS; Antweiler E; Losert H; Seibold M; Brandt MA; Van Den Ende AH; Fisher MC
Med Mycol; 2007 Aug; 45(5):385-93. PubMed ID: 17654264
[TBL] [Abstract][Full Text] [Related]
23. Population Structure and Genetic Diversity among Isolates of
Teixeira MM; Alvarado P; Roe CC; Thompson GR; Patané JSL; Sahl JW; Keim P; Galgiani JN; Litvintseva AP; Matute DR; Barker BM
mBio; 2019 Nov; 10(6):. PubMed ID: 31772050
[No Abstract] [Full Text] [Related]
24. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
[TBL] [Abstract][Full Text] [Related]
25. Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus.
Wiederhold NP; Patterson HP; Tran BH; Yates CM; Schotzinger RJ; Garvey EP
J Antimicrob Chemother; 2018 Feb; 73(2):404-408. PubMed ID: 29190379
[TBL] [Abstract][Full Text] [Related]
26. Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
Kantarcioğlu AS; Boekhout T; Yücel A; Altas K
Med Mycol; 2009 Mar; 47(2):169-76. PubMed ID: 18654925
[TBL] [Abstract][Full Text] [Related]
27. Chapter 2: coccidioidomycosis.
Deus Filho Ad
J Bras Pneumol; 2009 Sep; 35(9):920-30. PubMed ID: 19820819
[TBL] [Abstract][Full Text] [Related]
28. Molecular markers in the epidemiology and diagnosis of coccidioidomycosis.
Duarte-Escalante E; Frías-De-León MG; Zúñiga G; Martínez-Herrera E; Acosta-Altamirano G; Reyes-Montes Mdel R
Rev Iberoam Micol; 2014; 31(1):49-53. PubMed ID: 24270069
[TBL] [Abstract][Full Text] [Related]
29. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Karabıçak N; Alem N
Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
[TBL] [Abstract][Full Text] [Related]
30. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
Lass-Flörl C; Mayr A; Perkhofer S; Hinterberger G; Hausdorfer J; Speth C; Fille M
Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
[TBL] [Abstract][Full Text] [Related]
31. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
[TBL] [Abstract][Full Text] [Related]
32. Pathology of coccidioidomycosis in llamas and alpacas.
Fernandez JA; Hidalgo MN; Hodzic E; Diab SS; Uzal FA
J Vet Diagn Invest; 2018 Jul; 30(4):560-564. PubMed ID: 29790449
[TBL] [Abstract][Full Text] [Related]
33. A case report of Coccidioides posadasii meningoencephalitis in an immunocompetent host.
Lang R; Stokes W; Lemaire J; Johnson A; Conly J
BMC Infect Dis; 2019 Aug; 19(1):722. PubMed ID: 31420023
[TBL] [Abstract][Full Text] [Related]
34. The mysterious desert dwellers: Coccidioides immitis and Coccidioides posadasii, causative fungal agents of coccidioidomycosis.
Kollath DR; Miller KJ; Barker BM
Virulence; 2019 Dec; 10(1):222-233. PubMed ID: 30898028
[TBL] [Abstract][Full Text] [Related]
35. Life Cycle Dominates the Volatilome Character of Dimorphic Fungus
Higgins Keppler EA; Mead HL; Barker BM; Bean HD
mSphere; 2021 Apr; 6(2):. PubMed ID: 33853870
[TBL] [Abstract][Full Text] [Related]
36. Coccidioidomycosis.
Stockamp NW; Thompson GR
Infect Dis Clin North Am; 2016 Mar; 30(1):229-46. PubMed ID: 26739609
[TBL] [Abstract][Full Text] [Related]
37. Cotrimoxazole enhances the in vitro susceptibility of Coccidioides posadasii to antifungals.
Cordeiro Rde A; Astete-Medrano DJ; Marques FJ; Andrade HT; Perdigão Neto LV; Tavares JL; de Lima RA; Patoilo KK; Monteiro AJ; Brilhante RS; Rocha MF; de Camargo ZP; Sidrim JJ
Mem Inst Oswaldo Cruz; 2011 Dec; 106(8):1045-8. PubMed ID: 22241131
[TBL] [Abstract][Full Text] [Related]
38. Coccidioidomycosis in Latin America.
Laniado-Laborín R; Arathoon EG; Canteros C; Muñiz-Salazar R; Rendon A
Med Mycol; 2019 Feb; 57(Supplement_1):S46-S55. PubMed ID: 30690597
[TBL] [Abstract][Full Text] [Related]
39. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.
Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
Diagn Microbiol Infect Dis; 2011 Nov; 71(3):252-9. PubMed ID: 21917395
[TBL] [Abstract][Full Text] [Related]
40. In vitro inhibitory effect of antituberculosis drugs on clinical and environmental strains of Coccidioides posadasii.
de Aguiar Cordeiro R; Brilhante RS; Rocha MF; Fechine MA; Camargo ZP; Sidrim JJ
J Antimicrob Chemother; 2006 Sep; 58(3):575-9. PubMed ID: 16867997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
